STEVE GORLIN
CIK 1033742 · Chairman of the Board · last filed 2023-12-06
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$1.95M
Companies
8
Total Filings
87
Lifetime Open-Market Net
-$12.12M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| BIVI | Director | 715 | $1.33 | $951 | $281.4K | 12 | 2023-12-06 |
| ImmunityBio, Inc. (NK) Delisted | Director | 92,592 | — | — | -$13.52M | 19 | 2020-06-11 |
| POLARITYTE, INC. (PTE) Delisted | Director | 1,241 | $0.24 | $299 | -$319.0K | 3 | 2019-08-08 |
| POLARITYTE, INC. (COOL) Delisted | Director | 23,333 | $11.10 | $259.0K | $0 | 1 | 2017-11-13 |
| Innoveren Scientific, Inc. (MDVXW) Delisted | Director | 1,640,704 | — | — | $530.4K | 9 | 2017-11-01 |
| Innoveren Scientific, Inc. (MDVX.W) Delisted | Director | 961,503 | — | — | $1.10M | 3 | 2016-02-18 |
| MDXG | Director | 446,288 | $4.36 | $1.95M | -$193.8K | 2 | 2013-05-30 |
| Midatech Pharma US Inc. (DARA) Delisted | Director | — | — | — | $0 | 2 | 2012-05-17 |
Recent Filings · Page 7 of 9
87 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2012-09-12 | — | Sell (S) | −72,300 | -$195.2K | |
| 2012-07-03 | — | Sell (S) | −1,000,000 | -$1.55M | |
| 2012-05-17 | Midatech Pharma US Inc. (DARA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2012-03-05 | — | Sell (S) | −250,000 | -$250.0K | |
| 2011-12-29 | Midatech Pharma US Inc. (DARA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2011-12-19 | — | Grant (A) | — | $0 | |
| 2010-05-14 | — | Grant (A) | — | $0 | |
| 2010-04-02 | — | Buy (P) | +5,000 | $7.5K | |
| 2010-04-01 | — | Buy (P) | +4,000 | $6.2K | |
| 2010-03-29 | — | Buy (P) | +1,000 | $1.6K |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.